OTCMKTS:MCUJF Medicure (MCUJF) Stock Price, News & Analysis $0.70 0.00 (0.00%) (As of 11/8/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsSEC FilingsShort Interest About Medicure Stock (OTCMKTS:MCUJF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Medicure alerts:Sign Up Key Stats Today's Range$0.70▼$0.7050-Day Range$0.63▼$0.8052-Week Range$0.63▼$1.17VolumeN/AAverage Volume357 shsMarket Capitalization$7.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMedicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.Read More… The secret supplier behind NVIDIA, Tesla and Microsoft (Ad)The Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known supplier, which provides a crucial building block for AI.Click here for the ticker >>> Receive MCUJF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicure and its competitors with MarketBeat's FREE daily newsletter. Email Address MCUJF Stock News HeadlinesMedicure, Inc.: Medicure Announces Positive Settlement of Product Development and Supply ContractsOctober 25, 2024 | finanznachrichten.deMedicure Second Quarter 2024 Earnings: CA$0.12 loss per share (vs CA$0.024 profit in 2Q 2023)August 18, 2024 | finance.yahoo.com2025: Digital Asset Insights You Need to KnowAs we enter 2025, digital assets are seeing unprecedented growth and interest. In the past year alone, the market capitalization of digital assets has risen by over 20%, capturing the attention of investors worldwide. Our newest guide, "Navigating the Future: A Comprehensive Guide to Digital Assets in 2025," is designed to help you understand how to leverage these dynamic trends and insights for a stronger portfolio.November 10, 2024 | Darwin (Ad)Medicure, Inc.: Medicure Announces Closing of Asset Purchase Agreement with Canam Bioresearch for Acquisition of Intellectual PropertyAugust 15, 2024 | finanznachrichten.deMedicure Reports Financial Results for Quarter Ended March 31, 2024 and Annual General Meeting Director Election ResultsMay 28, 2024 | finance.yahoo.comMedicure Announces New Partnership Through Its Marley Drug Subsidiary to Provide Brenzavvy(R) as an Affordable Medication for Americans with Type 2 DiabetesDecember 5, 2023 | finance.yahoo.comMedicure approved to enrol patients in paediatric disease trialNovember 24, 2023 | msn.comMedicure Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric DiseaseNovember 23, 2023 | benzinga.comSee More Headlines MCUJF Stock Analysis - Frequently Asked Questions How have MCUJF shares performed this year? Medicure's stock was trading at $0.7754 on January 1st, 2024. Since then, MCUJF shares have decreased by 10.2% and is now trading at $0.6962. View the best growth stocks for 2024 here. How were Medicure's earnings last quarter? Medicure Inc. (OTCMKTS:MCUJF) released its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.09) earnings per share for the quarter. The business had revenue of $3.78 million for the quarter. Medicure had a negative net margin of 12.46% and a negative trailing twelve-month return on equity of 12.72%. How do I buy shares of Medicure? Shares of MCUJF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/14/2024Today11/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:MCUJF CUSIPN/A CIK1133519 Webwww.medicure.com Phone(204) 487-7412Fax204-488-9823EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-680,000.00 Net Margins-12.46% Pretax Margin-12.10% Return on Equity-12.72% Return on Assets-9.15% Debt Debt-to-Equity Ratio0.01 Current Ratio1.87 Quick Ratio1.42 Sales & Book Value Annual Sales$16.07 million Price / Sales0.45 Cash Flow$0.09 per share Price / Cash Flow7.85 Book Value$1.41 per share Price / Book0.49Miscellaneous Outstanding Shares10,440,000Free Float9,090,000Market Cap$7.27 million OptionableNot Optionable Beta1.01 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (OTCMKTS:MCUJF) was last updated on 11/10/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the ...Porter & Company | SponsoredI Got FiredStarting off with a few hundred bucks, it wasn't long before I started generating $1,000 a day. Then $10,00...Opportunistic Trader | SponsoredTrump’s Victory Just Kicked the Door Open to a…This story is about a division that has been splitting America apart at the seams for the past three and a hal...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicure Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.